BioIntelliSense, Inc

BioIntelliSense develops the BioButton system, an FDA-cleared continuous patient monitoring solution that combines medical-grade wearable devices with clinical intelligence software. The system monitors vital signs and biometric data for patients both in hospital facilities and at home, designed to detect early signs of patient deterioration through continuous data collection and analysis.

The company's monitoring platform includes the BioButton wearable device, flexible gateway options (BioMobile app, BioHub Cellular, and BioHub Wi-Fi), and BioDashboard exception management software. The system is designed to support hospital initiatives including length of stay reduction, telemetry overuse reduction, and virtual care programs. Published studies demonstrate the platform's impact on reducing unplanned ICU admissions, rapid response team activations, and hospital readmissions.

BioIntelliSense serves hospitals, health systems, and post-acute care organizations, with documented implementations at institutions like Houston Methodist Hospital. A 2024 observational study published in the Journal of Clinical Medicine evaluated nearly 12,000 hospitalized patients using the system. The company recently received FDA clearance for a rechargeable BioButton Multi-Patient wearable designed to scale virtual care programs cost-effectively.

Organizations should consider BioIntelliSense when implementing evidence-based continuous monitoring programs with documented clinical outcomes. The system is particularly suited for institutions pursuing multiple initiatives simultaneously—such as reducing telemetry overuse while expanding virtual care capabilities—due to the platform's flexibility across care settings.

Expect a hardware-software hybrid implementation requiring gateway infrastructure and clinical workflow integration. The rechargeable multi-patient device model suggests suitability for organizations monitoring sufficient patient volumes to justify device inventory management.

BioIntelliSense operates exclusively in healthcare with FDA-cleared medical devices designed for hospital and post-acute care monitoring. The company's platform addresses specific healthcare quality metrics including ICU admission rates, rapid response team activations, and 30-day readmissions. Solutions support healthcare-specific initiatives such as telemetry overuse reduction programs, virtual rounding optimization, and Rural Health Transformation Program applications. The company maintains HIPAA compliance and partners with healthcare-specific organizations like Hicuity Health for integrated virtual care delivery.

Mid-to-large hospital systems and health networks with patient volumes justifying continuous monitoring infrastructure investment. Organizations actively pursuing quality improvement initiatives around ICU utilization, length of stay reduction, or virtual care expansion. Health systems with established or developing transitional care programs requiring evidence-based monitoring solutions that support RPM reimbursement and readmission prevention goals.